Mouse anti Yellow fever virus antibody, clone 2D12
recognizes the envelope protein of the wild (Asibi) and vaccine strains of yellow fever virus. The clone has been reported to have neutralising activity against the Asibi strain (Schlessinger et al. 1984
). No cross reactivity with other flaviviruses has been reported.
- Target Species
- Product Form
- Ascites - Liquid
- Preservative Stabilisers
- None Present
- 17D strain of yellow fever virus
- Store at -20oC only.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of Yellow Fever Virus antibody
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Application Based External Images
Product Specific References
References for Yellow Fever Virus antibody
Schlesinger, J.J. et al. (1983) Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.
Virology. 125 (1): 8-17.
Schlesinger, J.J. & Brandriss, M.W. (1983) 17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor.
J Gen Virol. 64 (Pt 6): 1255-62.
Schlesinger, J.J. et al. (1984) Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies.
J Gen Virol. 65 ( Pt 10): 1637-44.
Gandini, M. et al. (2011) Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles.
Mem Inst Oswaldo Cruz. 106 (5): 594-605.
Monath, T.P. et al. (1986) Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens.
J Clin Microbiol. 23 (1): 129-34.
Brandriss, M.W. et al. (1986) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
J Gen Virol. 67 ( Pt 2): 229-34.
Op De Beeck, A. et al. (2003) Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope.
J Virol. 77 (2): 813-20.
Izurieta, R.O. et al. (2009) Anamnestic immune response to dengue and decreased severity of yellow Fever.
J Glob Infect Dis. 1 (2): 111-6.
Thonnon, J. et al. (1998) Re-emergence of yellow fever in Senegal in 1995.
Am J Trop Med Hyg. 59 (1): 108-14.
Thonnon, J.et al. (1998) Yellow fever outbreak in Kaffrine, Senegal 1996: epidemiological and entomological findings.
Trop Med Int Health. 3 (11): 872-7.
Op De Beeck, A. et al. (2004) The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals.
J Virol. 78 (22): 12591-602.
Ciczora, Y. et al. (2010) Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein.
J Gen Virol. 91 (Pt 2): 404-14.
Vratskikh, O. et al. (2013) Dissection of antibody specificities induced by yellow fever vaccination.
PLoS Pathog. 9 (6): e1003458.